Abstract: A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount of Lactobacillus paracasei GMNL-133, an effective amount of Lactobacillus reuteri GMNL-89, and a pharmaceutically acceptable carrier, wherein the Lactobacillus paracasei GMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and the Lactobacillus reuteri GMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

Abstract: A method and a User Equipment (UE) for beam operations are provided. The method includes monitoring at least one of a plurality of Control Resource Sets (CORESETs) configured for the UE within an active Bandwidth Part (BWP) of a serving cell in a time slot; and applying a first Quasi Co-Location (QCL) assumption of a first CORESET of a set of one or more of the monitored at least one of the plurality of CORESETs to receive a Downlink (DL) Reference Signal (RS), wherein the first CORESET is associated with a monitored search space configured with a lowest CORESET Identity (ID) among the set of one or more of the monitored at least one of the plurality of CORESETs.

Abstract: Some of the present implementations provide a method for a user equipment (UE) for receiving a power saving signal. The method receives, from a base station, a power saving signal comprising a minimum applicable K0 (K0min) that indicates a minimum scheduling offset restriction between a physical downlink control channel (PDCCH) and a physical downlink shared channel (PDSCH). The method determines an application delay based on a predefined value. The method then applies the minimum scheduling offset restriction after the application delay.

Abstract: A method for PDCCH monitoring performed by a UE is provided. The method includes performing the PDCCH monitoring in a first group associated with at least one first PDCCH monitoring configuration; receiving, from a base station, DCI comprising an indicator; performing the PDCCH monitoring in a second group associated with at least one second PDCCH monitoring configuration; and stopping the PDCCH monitoring in the first group after receiving the indicator.

Abstract: The present invention relates to a plant growth regulator of elevating anti-stress ability and use thereof. The plant growth regulator, which is consisted of Lactobacillus fermenting culture solution, has excellent thermostability and safety without any side effect, significantly elevating ability against biotic and abiotic stresses. Therefore, the Lactobacillus fermenting culture solution can be applied as the plant growth regulator or a use in preparation of a composition for elevating anti-stress ability of a plant.

Abstract: A probiotic composition of improving memory and learning ability is disclosed. The probiotic composition comprises Lactobacillus acidophilus GMNL-185 and Lactobacillus rhamnosus GMNL-680, wherein the Lactobacillus acidophilus GMNL-185 was deposited in the China Center for Type Culture Collection in Wuhan, China on Nov. 3, 2017 under an accession number CCTCC NO. M 2017764, and the Lactobacillus rhamnosus GMNL-680 was deposited in the China Center for Type Culture Collection in Wuhan, China on Nov. 3, 2017 under an accession number CCTCC NO. M 2017766, wherein a ratio of a number of bacteria of the Lactobacillus acidophilus GMNL-185 to a number of bacteria of the Lactobacillus rhamnosus GMNL-680 is 1:1.

Abstract: A composition with Lactobacillus paracasei and a method to treat nasopharyngeal carcinoma through induction of pyroptosis or cell cycle arrest; Lactobacillus paracasei GMNL-653 or heat-killed whole-bacterial liquids thereof are taken as effective ingredients for inhibiting proliferations of nasopharyngeal carcinoma cells or reducing a probability of nasopharyngeal carcinoma development through pyroptosis or cell cycle arrest instead of the mechanism of apoptosis.

Abstract: A method for preventing or treating oral cancer includes administering a composition comprising Lactobacillus paracasei or a supernatant of the heat-killed Lactobacillus paracasei. A composition that contains an active ingredient with anti-oral cancer effect. The active ingredient is Lactobacillus paracasei GMNL-346 or the supernatant of the heat-killed GMNL-346. The deposition number of the Lactobacillus paracasei GMNL-346 is BCRC 910953 or CCTCC M 2019983.

Abstract: The invention provides an extracellular vesicle and a nucleotide fragment isolated from Lactobacillus paracasei GM-080 with the deposition number BCRC 910220 and CCTCC M 204012 and use thereof. The invention also relates to a method for modulating immune function comprising administering a composition including the extracellular vesicle and the nucleotide fragment.

Abstract: A strain of Lactobacillus paracasei for promoting hair growth, a hair product having same, and a use thereof are disclosed. The strain of Lactobacillus paracasei is Lactobacillus paracasei GMNL-653, which was deposited at the China Center for Type Culture Collection in Wuhan, China on Apr. 25, 2016 under an accession number CCTCC NO. M 2016226.

Abstract: The present invention provides a Lactobacillus composition and a use thereof for improving anxiety caused by antibiotics, wherein the Lactobacillus composition comprises Lactobacillus plantarum GMNL-141, Lactobacillus rhamnosus GM-020, Lactobacillus acidophilus GMNL-185, or a combination thereof. The Lactobacillus composition can effectively improve imbalance of an individual's intestinal flora caused by antibiotics to help stabilize and increase species richness and increase the synthesis of mood-stabilizing compounds, including flavonoids, flavonols, isoquinoline alkaloids, niacinamide, nicotinamide, and short-chain fatty acids in intestine, and thus effectively improve antibiotic-induced with anxiety disorders.

Abstract: A composition having Lactobacillus Plantarum strain GMNL-662 for promoting bone regrowth is provided. The Lactobacillus Plantarum strain GMNL-662 has an ability to promote the expression of osteogenic genes, inhibit the expression of osteoclast related genes, and promote the expression of osteogenesis-related cytokine TGF-?, so that the bone loss is improved.

Abstract: The present invention relates to a topical composition of facilitating wound healing and reducing scars, which includes an inactivated culture of Lactobacillus species as an effective ingredient and can significantly facilitate wound healing as well as reducing scars, thereby can be applied to a method of facilitating wound healing and reducing scars.

Abstract: Present invention discloses a Lactobacillus composition comprising Lactobacillus reuteri GMNL-263 which is a strain of heat-killed dead bacteria and has the effect of lowering blood pressure by inhibition of proinflammatory cytokine IL-1? and enhancement the growth of Bifidobacterium, and said Lactobacillus composition is a pharmaceutical composition, nutritional supplement, health food or a combination thereof.

Abstract: A probiotic composition for improving an effect of a chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is disclosed in the present disclosure. The probiotic composition comprises an effective amount of Lactobacillus paracasei GMNL-133, an effective amount of Lactobacillus reuteri GMNL-89, and a pharmaceutically acceptable carrier, wherein the Lactobacillus paracasei GMNL-133 was deposited in the China Center for Type Culture Collection on Sep. 26, 2011 under an accession number CCTCC NO. M 2011331, and the Lactobacillus reuteri GMNL-89 was deposited in the China Center for Type Culture Collection on Nov. 19, 2007 under an accession number CCTCC NO. M 207154. A method for improving the effect of the chemotherapeutic drug of Gemcitabine on inhibiting pancreatic cancer is further disclosed in the present disclosure.

Abstract: A method for preventing or treating oral cancer, including administering a composition comprising Lactobacillus paracasei or a supernatant of the heat-killed Lactobacillus paracasei. A composition that contains an active ingredient with anti-oral cancer effect. The active ingredient is Lactobacillus paracasei GMNL-346 or the supernatant of the heat-killed GMNL-346, and the deposition number of the Lactobacillus paracasei GMNL-346 is BCRC 910953 or CCTCC M 2019983.

Abstract: The present invention provides a use for probiotic preparing skin care composition, wherein the probiotic comprises Lactobacillus plantarum (GMNL-6) with preservation number of BCRC 910777 or CCTCC M 2017765. The composition may be externally-coating drug, pharmaceuticals for external use, care products for external use or cosmetics, and may achieve the effects of improving the skin conditions or aesthetic appearance by promoting secretion of collagen or expression of ceramide synthase.

Abstract: A composition having Lactobacillus Plantarum strain GMNL-662 for promoting bone regrowth is provided. The Lactobacillus Plantarum strain GMNL-662 has an ability to promote the expression of osteogenic genes, inhibit the expression of osteoclast related genes, and promote the expression of osteogenesis-related cytokine TGF-?, so that the bone loss is improved.

Abstract: The present invention provides a composition for preventing stroke and ameliorating the severity of stroke and comprises an effective dose of Lactobacillus reuteri GMNL-89 and Lactobacillus paracasei GMNL-133; the accession number of Lactobacillus reuteri GMNL-89 is CCTCC M207154 and the accession number of Lactobacillus paracasei GMNL-133 is CCTCC M2011331. The composition can be taken as a dietary supplement and be given continuously after a stroke, and said composition has the effects of ameliorating cerebral infarction, motor function, and intestinal microbiota after a stroke.

Abstract: The present invention provides a pharmaceutical composition and a food product for inhibiting gastritis induced by gastric Helicobacter pylori, comprising Lactobacillus selected from a group composed of Lactobacillus rhamnosus GM-020 (also known as GMNL-74) with deposited number CCTCC M203098; Lactobacillus acidophilus GMNL-185 with deposited number CCTCC M2017764; and Lactobacillus plantarum GMNL-662 with deposited number CCTCC M2016571; and any two of the above bacteria.